logo
As nicotine pouches' popularity soars, they're also responsible for more poisonings in young kids, study finds

As nicotine pouches' popularity soars, they're also responsible for more poisonings in young kids, study finds

CNN7 hours ago
Nicotine pouches are a fast-growing source of nicotine poisoning in young children, according to a new study.
Researchers at Nationwide Children's Hospital in Ohio analyzed more than a decade's worth of data, examining over 134,000 cases of children under 6 who accidentally ingested nicotine through products like vapes, gums, and lozenges. Most types of exposures fell after 2016. But one delivery method — nicotine pouches — shot up, rising more than 760% between 2020 and 2023.
'It's a high-concentration nicotine product, and it tastes good,' said Dr. Natalie Rine, director of the Central Ohio Poison Center at Nationwide Children's Hospital and co-author of the study, published Monday in the journal Pediatrics. 'There's nothing telling the kid, 'this is bad, you should spit it out' … and that's where you get into trouble.'
The miniature white packets that users tuck between their lip and gum hit US shelves in 2014. They don't contain tobacco but are instead filled with nicotine, either synthetically or naturally derived, along with flavorings and sweeteners.
The discreet, sweet and smokeless nature of nicotine pouches has raised concerns among public health advocates, who are closely watching their rising popularity among teens and young adults. They've become the second most-used nicotine product among young people, according to the US Centers for Disease Control and Prevention. The National Youth Tobacco Survey found that nicotine pouch use among teens doubled between 2021 and 2024.
Still, the overall user base remains small. Just 0.5% of Americans use nicotine pouches, compared with 9% who smoke cigarettes and 3% who vape or use e-cigarettes, according to US Census Bureau data.
Levels of nicotine in pouches can vary from 3 to 12 milligrams per pouch. At their lowest doses, they deliver more of the stimulant than a cigarette, and even small amounts of nicotine can be dangerous for small children. Ingesting just 1 to 2 milligrams — less than what's inside a single regular-strength pouch — can cause nausea, vomiting and tremors, among other serious symptoms, according to the National Library of Medicine.
The study found that nicotine pouches were associated with a 150% greater risk of serious medical effects and were twice as likely to lead to hospitalization than other smokeless nicotine products swallowed by children, like gums, lozenges, e-liquids, tablets and powders.
Although the vast majority of pediatric nicotine ingestions resulted in little to no harm, more than 1,600 children had serious medical outcomes, the study found. Two children died after ingesting liquid nicotine.
Rine recommends that parents avoid using nicotine pouches in front of children to keep them from imitating potentially risky adult behaviors. She also suggests keeping nicotine products physically out of kids' reach and to have conversations with other caretakers, like babysitters and extended family, about doing the same.
If a child may have ingested a nicotine pouch, Rine says, the best first step is to call Poison Control at 1-800-222-1222. Trained staff can guide caregivers based on a child's symptoms and help them decide if emergency care is needed.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Exact Sciences Schedules Second Quarter 2025 Earnings Call
Exact Sciences Schedules Second Quarter 2025 Earnings Call

Yahoo

time37 minutes ago

  • Yahoo

Exact Sciences Schedules Second Quarter 2025 Earnings Call

MADISON, Wis., July 14, 2025--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2025 financial results after the close of the U.S. financial markets on August 6, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Second quarter 2025 webcast & conference call details Date: Wednesday, August 6, 2025 Time: 5 p.m. ET Webcast: The live webcast can be accessed at Telephone: Domestic callers, dial 888-330-2384International callers, dial +1 240-789-2701 Access code for both domestic and international callers: 4437608 A replay of the webcast will be available at The webcast, conference call, and replay are open to all interested parties. About Exact Sciences Corp. A leading provider of cancer screening and diagnostic tests, Exact Sciences helps patients and health care providers make timely, informed decisions before, during, and after a cancer diagnosis. The company's growing portfolio includes well-established brands such as Cologuard® and Oncotype DX®, along with innovative solutions like Oncodetect™ for molecular residual disease and recurrence monitoring. Exact Sciences continues to invest in a robust pipeline of advanced cancer diagnostics aimed at improving outcomes. For more information, visit follow @ExactSciences on X, or connect on LinkedIn and Facebook. View source version on Contacts Investor Contact:Derek Leckow608-893-0009investorrelations@ 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤

ACG Refreshes Preventive Care in IBD Guidance
ACG Refreshes Preventive Care in IBD Guidance

Medscape

timean hour ago

  • Medscape

ACG Refreshes Preventive Care in IBD Guidance

The American College of Gastroenterology has issued an updated clinical practice guideline on preventive care for patients with inflammatory bowel disease (IBD) that covers vaccinations, cancer surveillance, bone health monitoring, lifestyle counseling, and other important 'health maintenance' issues. 'Patients with IBD often consider their gastroenterologist to be the primary provider of care. Because more than 70% of patients with IBD will at some time be on medications that will affect the immune system, it is essential that the gastroenterology team promote vaccinations and other health maintenance activities,' said the writing group, led by Francis Farraye, MD, director, Inflammatory Bowel Disease Center, Mayo Clinic, Jacksonville, Florida. The panel noted that referral to dermatology, endocrinology, gynecology, primary care, and psychiatry 'may be necessary on a case-by-case basis. Coordination between the gastroenterology team and other providers is crucial for improving the quality of care that we provide to our patients living with IBD.' The 27-page updated guideline on preventive care in IBD was published earlier this month in The American Journal of Gastroenterology , along with a one-page visual highlights summary. The update provides 12 recommendation statements and 11 key concepts. It replaces the 2017 ACG guideline on preventive care in IBD. Prioritize Vaccinations 'Patients with IBD are at increased risk for infections as a consequence of their disease, and this risk may be amplified by certain immune-modifying therapies,' the writing group noted. They strongly recommend that all adults with IBD aged 50 years and older with no prior pneumococcal vaccination receive the pneumococcal conjugate vaccine (PCV) 20 or PCV21. There is a conditional recommendation that adults aged 19-49 years on immune-modifying therapy and with no prior pneumococcal vaccination also receive the PCV20 or PCV21 vaccine. Patients with IBD who previously received a pneumococcal vaccine should follow revaccination advice from the CDC. Vaccination against herpes zoster with the two-dose inactive recombinant herpes zoster vaccine is advised for patients with IBD aged 50 years or more and for younger patients about to start or already on immune-modifying therapy (both conditional recommendations). Other conditional recommendations include vaccination against SARS-CoV-2 in accordance with national guidelines and live rotavirus vaccine for children with in-utero exposure to biologics. In addition, all adults with IBD should receive annual influenza vaccines; those receiving immune-modifying therapies and their household contacts should receive the nonlive trivalent inactivated influenza vaccine but not the live inhaled influenza vaccine. Respiratory syncytial virus (RSV) vaccine is advised for all patients aged 75 and older and for those aged 50-74 years with certain chronic medical conditions or other risk factors for severe RSV disease. Household members of patients receiving immune-modifying therapies can receive live vaccines with certain precautions. Vaccinations against tetanus, diphtheria, and pertussis (Tdap), hepatitis A virus, human papillomavirus (HPV), and meningococcus should be administered according to CDC recommendations. Adults with IBD should receive vaccination against hepatitis B if not immune. Skin and Cervical Cancer Surveillance 'In addition to vaccination issues, it is important to identify subgroups of patients with IBD that have an increased risk of developing cervical cancer, nonmelanoma skin cancer (NMSC), and melanoma,' the panel said. In women with IBD on immune-modifying therapies, there is a conditional recommendation for annual cervical cancer screening within a year of sexual activity onset; in women younger than 30 years, screening should continue for 3 consecutive years before increasing to every 3 years. Annual screening for melanoma (independent of biologic therapy) and for NMSC (particularly in adults aged 50+) is also suggested (conditional recommendations). Bone and Mental Health Patients with IBD are at increased risk for bone loss, which can lead to osteopenia and osteoporosis. The guideline suggests screening for osteoporosis with bone mineral density testing at the time of diagnosis and periodically after diagnosis (conditional recommendation). Given data showing worse outcomes among smokers with IBD, smoking cessation counseling is strongly encouraged. The guideline also addresses the mental health of patients with IBD. 'Current evidence suggests that mood disorders, in particular depression and anxiety, are more prevalent in patients with IBD than the background population, the panel noted. Therefore, they recommend that all patients with IBD be screened for depression and anxiety at baseline and annually. Patients who screen positive for anxiety and/or depression should be referred for counseling/therapy.

‘Ticks EVERYWHERE?': Sightings and bites in the D.C. region heighten worries
‘Ticks EVERYWHERE?': Sightings and bites in the D.C. region heighten worries

Washington Post

timean hour ago

  • Washington Post

‘Ticks EVERYWHERE?': Sightings and bites in the D.C. region heighten worries

Michael Raupp is used to pulling bugs off his body. As an entomology professor and author of a blog that introduces readers to a bug a week, the 73-year-old spends a lot of time outdoors conducting field research. His work takes him into forests, meadows and other patches of greenery in Maryland, and afterward, it's not unusual for him to find winged or multi-legged creatures hitchhiking on him.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store